Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia.

van der Straten L, Kater AP, Doorduijn JK, van den Broek EC, Posthuma EFM, Dinmohamed AG, Levin MD.

Ann Hematol. 2020 Mar 19. doi: 10.1007/s00277-020-03994-8. [Epub ahead of print]

PMID:
32193628
2.

The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands.

van der Straten L, Levin MD, Visser O, Blijlevens NMA, Cornelissen JJ, Doorduijn JK, Kater AP, Dinmohamed AG.

Br J Haematol. 2020 Mar;188(6):e109-e112. doi: 10.1111/bjh.16391. Epub 2020 Jan 28. No abstract available.

PMID:
31991479
3.

Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling.

Hofland T, Endstra S, Gomes CKP, de Boer R, de Weerdt I, Bobkov V, Riedl JA, Heukers R, Smit MJ, Eldering E, Levin MD, Kater AP, Tonino SH.

Hemasphere. 2019 Oct 30;3(6):e308. doi: 10.1097/HS9.0000000000000308. eCollection 2019 Dec.

4.

Rare but Serious: Ibrutinib Induced Liver Failure.

Kleijwegt FS, Roda AA, Rolvink J, Kater AP, Kersten MJ, Vos JMI.

Hemasphere. 2019 Oct 22;3(6):e307. doi: 10.1097/HS9.0000000000000307. eCollection 2019 Dec. No abstract available.

5.

Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study.

Leeksma AC, Baliakas P, Moysiadis T, Puiggros A, Plevova K, van der Kevie-Kersemaekers AM, Posthuma H, Rodriguez-Vicente AE, Tran AN, Barbany G, Mansouri L, Gunnarsson R, Parker H, van den Berg E, Bellido M, Davis Z, Wall M, Scarpelli I, Österborg A, Hansson L, Jarosova M, Ghia P, Poddighe P, Espinet B, Pospisilova S, Tam C, Ysebaert L, Nguyen-Khac F, Oscier D, Haferlach C, Schoumans J, Stevens-Kroef M, Eldering E, Stamatopoulos K, Rosenquist R, Strefford JC, Mellink C, Kater AP.

Haematologica. 2020 Jan 23. pii: haematol.2019.239947. doi: 10.3324/haematol.2019.239947. [Epub ahead of print]

6.

Survival continues to increase in chronic lymphocytic leukaemia: a population-based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016.

van der Straten L, Levin MD, Visser O, Posthuma EFM, Doorduijn JK, Kater AP, Dinmohamed AG.

Br J Haematol. 2020 Jan 20. doi: 10.1111/bjh.16397. [Epub ahead of print] No abstract available.

PMID:
31958141
7.

Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.

Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn JK, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Jain P, Frigault MM, Izumi R, Nguyen D, Patel P, Yin M, Długosz-Danecka M.

Leukemia. 2019 Nov;33(11):2762-2766. doi: 10.1038/s41375-019-0575-9. Epub 2019 Sep 26. No abstract available.

PMID:
31558766
8.

Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.

Deng R, Gibiansky L, Lu T, Li X, Lu D, Li C, Girish S, Wang J, Boyer M, Shankar N, Humphrey K, Freise KJ, Salem AH, Seymour JF, Kater AP, Miles D.

Leuk Lymphoma. 2020 Jan;61(1):56-65. doi: 10.1080/10428194.2019.1657575. Epub 2019 Sep 24.

PMID:
31549889
9.

Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.

Ruchlemer R, Ben-Ami R, Bar-Meir M, Brown JR, Malphettes M, Mous R, Tonino SH, Soussain C, Barzic N, Messina JA, Jain P, Cohen R, Hill B, Mulligan SP, Nijland M, Herishanu Y, Benjamini O, Tadmor T, Okamoto K, Arthurs B, Gottesman B, Kater AP, Talha M, Eichhorst B, Korem M, Bogot N, De Boer F, Rowe JM, Lachish T.

Mycoses. 2019 Dec;62(12):1140-1147. doi: 10.1111/myc.13001. Epub 2019 Oct 22.

PMID:
31520441
10.

Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes.

Hofland T, de Weerdt I, Ter Burg H, de Boer R, Tannheimer S, Tonino SH, Kater AP, Eldering E.

J Immunol. 2019 Oct 15;203(8):2100-2109. doi: 10.4049/jimmunol.1900321. Epub 2019 Sep 11.

PMID:
31511358
11.

Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.

de Weerdt I, Hofland T, de Boer R, Dobber JA, Dubois J, van Nieuwenhuize D, Mobasher M, de Boer F, Hoogendoorn M, Velders GA, van der Klift M, Remmerswaal EBM, Bemelman FJ, Niemann CU, Kersting S, Levin MD, Eldering E, Tonino SH, Kater AP.

Blood Adv. 2019 Sep 10;3(17):2642-2652. doi: 10.1182/bloodadvances.2019000360.

12.

Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia.

Hofland T, Eldering E, Kater AP, Tonino SH.

Int J Mol Sci. 2019 Sep 3;20(17). pii: E4315. doi: 10.3390/ijms20174315. Review.

13.

Ibrutinib and Venetoclax for First-Line Treatment of CLL.

Kater AP, Levin MD, Niemann CU.

N Engl J Med. 2019 Aug 22;381(8):788-789. doi: 10.1056/NEJMc1908754. No abstract available.

PMID:
31433936
14.

Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.

Deng R, Gibiansky L, Lu T, Agarwal P, Ding H, Li X, Kshirsagar S, Lu D, Li C, Girish S, Wang J, Boyer M, Humphrey K, Freise KJ, Salem AH, Seymour JF, Kater AP, Miles D.

Clin Pharmacokinet. 2019 Dec;58(12):1621-1634. doi: 10.1007/s40262-019-00788-8.

PMID:
31209657
15.

Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy.

van Bruggen JAC, Martens AWJ, Fraietta JA, Hofland T, Tonino SH, Eldering E, Levin MD, Siska PJ, Endstra S, Rathmell JC, June CH, Porter DL, Melenhorst JJ, Kater AP, van der Windt GJW.

Blood. 2019 Jul 4;134(1):44-58. doi: 10.1182/blood.2018885863. Epub 2019 May 10.

PMID:
31076448
16.

Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.

Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F, Davis Z, Rigolin GM, Visentin A, Xochelli A, Delgado J, Baran-Marszak F, Stalika E, Abrisqueta P, Durechova K, Papaioannou G, Eclache V, Dimou M, Iliakis T, Collado R, Doubek M, Calasanz MJ, Ruiz-Xiville N, Moreno C, Jarosova M, Leeksma AC, Panayiotidis P, Podgornik H, Cymbalista F, Anagnostopoulos A, Trentin L, Stavroyianni N, Davi F, Ghia P, Kater AP, Cuneo A, Pospisilova S, Espinet B, Athanasiadou A, Oscier D, Haferlach C, Stamatopoulos K; ERIC, the European Research Initiative on CLL.

Blood. 2019 Mar 14;133(11):1205-1216. doi: 10.1182/blood-2018-09-873083. Epub 2019 Jan 2.

17.

Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.

Kater AP, Kersting S, van Norden Y, Dubois J, Dobber JA, Mellink CH, Evers LM, Croon-de Boer F, Schreurs J, van der Spek E, Visser H, Idink C, Wittebol S, Hoogendoorn M, Tonino SH, Mobasher M, Levin MD; HOVON CLL study group.

Blood Adv. 2018 Dec 26;2(24):3566-3571. doi: 10.1182/bloodadvances.2018019422.

18.

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.

Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, Verdugo M, Wu J, Punnoose EA, Jiang Y, Wang J, Boyer M, Humphrey K, Mobasher M, Kipps TJ.

J Clin Oncol. 2019 Feb 1;37(4):269-277. doi: 10.1200/JCO.18.01580. Epub 2018 Dec 3.

19.

Ibrutinib: searching for a partner drug.

Kater AP, Brown JR.

Lancet Oncol. 2019 Jan;20(1):3-5. doi: 10.1016/S1470-2045(18)30861-1. Epub 2018 Dec 3. No abstract available.

PMID:
30522966
20.

Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.

de Weerdt I, Hofland T, Lameris R, Endstra S, Jongejan A, Moerland PD, de Bruin RCG, Remmerswaal EBM, Ten Berge IJM, Liu N, van der Stelt M, Faber LM, Levin MD, Eldering E, Tonino SH, de Gruijl TD, van der Vliet HJ, Kater AP.

Blood. 2018 Nov 22;132(21):2260-2272. doi: 10.1182/blood-2017-12-822569. Epub 2018 Sep 13. Erratum in: Blood. 2019 Oct 10;134(15):1271-1272.

PMID:
30213872
21.

Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.

Kater AP, van Oers MHJ, van Norden Y, van der Straten L, Driessen J, Posthuma WFM, Schipperus M, Chamuleau MED, Nijland M, Doorduijn JK, Van Gelder M, Hoogendoorn M, De Croon F, Wittebol S, Kerst JM, Marijt EWA, Raymakers RAP, Schaafsma MR, Dobber JA, Kersting S, Levin MD; HOVON CLL study group.

Haematologica. 2019 Jan;104(1):147-154. doi: 10.3324/haematol.2018.193854. Epub 2018 Aug 16.

22.

Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.

Leeksma AC, Taylor J, Wu B, Gardner JR, He J, Nahas M, Gonen M, Alemayehu WG, Te Raa D, Walther T, Hüllein J, Dietrich S, Claus R, de Boer F, de Heer K, Dubois J, Dampmann M, Dürig J, van Oers MHJ, Geisler CH, Eldering E, Levine RL, Miller V, Mughal T, Lamanna N, Frattini MG, Heaney ML, Zelenetz A, Zenz T, Abdel-Wahab O, Kater AP.

Leukemia. 2019 Feb;33(2):390-402. doi: 10.1038/s41375-018-0215-9. Epub 2018 Jul 23.

23.

Autoimmune cytopenias in chronic lymphocytic leukemia: a concise review and treatment recommendations.

De Back TR, Kater AP, Tonino SH.

Expert Rev Hematol. 2018 Aug;11(8):613-624. doi: 10.1080/17474086.2018.1489720. Epub 2018 Jul 14. Review.

PMID:
29923432
24.

Venetoclax-Rituximab in Chronic Lymphocytic Leukemia.

Seymour JF, Mobasher M, Kater AP.

N Engl J Med. 2018 May 31;378(22):2143-2144. doi: 10.1056/NEJMc1805135. No abstract available.

PMID:
29847765
25.

Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy.

van der Straten L, Dinmohamed AG, Westerweel PE, Langerak AW, Riedl J, Doorduijn JK, Kater AP, Levin MD.

Leuk Lymphoma. 2018 Nov;59(11):2757-2761. doi: 10.1080/10428194.2018.1452215. Epub 2018 Apr 4. No abstract available.

PMID:
29616852
26.

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP.

N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976.

27.

Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.

Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadhi S, Kasar S, Kater AP, Doorduijn JK, Gao L, Lager JJ, Wu B, Egile C, Kersten MJ.

Lancet Haematol. 2018 Apr;5(4):e170-e180. doi: 10.1016/S2352-3026(18)30030-9. Epub 2018 Mar 14. Erratum in: Lancet Haematol. 2018 Jun;5(6):e240.

28.

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.

Malcikova J, Tausch E, Rossi D, Sutton LA, Soussi T, Zenz T, Kater AP, Niemann CU, Gonzalez D, Davi F, Gonzalez Diaz M, Moreno C, Gaidano G, Stamatopoulos K, Rosenquist R, Stilgenbauer S, Ghia P, Pospisilova S; European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) — TP53 network.

Leukemia. 2018 May;32(5):1070-1080. doi: 10.1038/s41375-017-0007-7. Epub 2018 Feb 2. Review.

29.

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies.

Kater AP, Tonino SH, Spiering M, Chamuleau MED, Liu R, Adewoye AH, Gao J, Dreiling L, Xin Y, Doorduijn JK, Kersten MJ; HOVON Lunenburg Lymphoma Phase I/II Consortium.

Blood Cancer J. 2018 Feb 12;8(2):16. doi: 10.1038/s41408-018-0055-x. No abstract available.

30.

Relative survival reaches a plateau in hairy cell leukemia: a population-based analysis in The Netherlands.

Dinmohamed AG, Posthuma EFM, Visser O, Kater AP, Raymakers RAP, Doorduijn JK.

Blood. 2018 Mar 22;131(12):1380-1383. doi: 10.1182/blood-2017-12-820381. Epub 2018 Jan 30. No abstract available.

PMID:
29382643
31.

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.

Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W.

Lancet. 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2. Epub 2017 Dec 11.

PMID:
29241979
32.

Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands.

Kersting S, Neppelenbroek SIM, Visser HPJ, van Gelder M, Levin MD, Mous R, Posthuma W, van der Straaten HM, Kater AP.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):52-57. doi: 10.1016/j.clml.2017.09.015. Epub 2017 Sep 25.

PMID:
29097160
33.

Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling.

Singh SP, Pillai SY, de Bruijn MJW, Stadhouders R, Corneth OBJ, van den Ham HJ, Muggen A, van IJcken W, Slinger E, Kuil A, Spaargaren M, Kater AP, Langerak AW, Hendriks RW.

Oncotarget. 2017 May 26;8(42):71981-71995. doi: 10.18632/oncotarget.18234. eCollection 2017 Sep 22.

34.

CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis.

van Attekum MHA, van Bruggen JAC, Slinger E, Lebre MC, Reinen E, Kersting S, Eldering E, Kater AP.

Haematologica. 2017 Dec;102(12):2069-2076. doi: 10.3324/haematol.2016.157206. Epub 2017 Sep 29.

35.

Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.

Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel S, Fischer K, Wendtner CM, Nösslinger T, Ghia P, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E, Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M.

Lancet Haematol. 2017 Oct;4(10):e475-e486. doi: 10.1016/S2352-3026(17)30171-0. Epub 2017 Sep 12.

PMID:
28916311
36.

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.

de Weerdt I, Koopmans SM, Kater AP, van Gelder M.

Haematologica. 2017 Oct;102(10):1629-1639. doi: 10.3324/haematol.2017.164103. Epub 2017 Aug 3. Review.

37.

Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk.

van Attekum MH, Eldering E, Kater AP.

Haematologica. 2017 Sep;102(9):1469-1476. doi: 10.3324/haematol.2016.142679. Epub 2017 Aug 3. Review.

38.

Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition.

Slinger E, Thijssen R, Kater AP, Eldering E.

Leukemia. 2017 Dec;31(12):2601-2607. doi: 10.1038/leu.2017.129. Epub 2017 May 2.

PMID:
28462919
39.

Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia.

van Attekum MHA, Terpstra S, Slinger E, von Lindern M, Moerland PD, Jongejan A, Kater AP, Eldering E.

Oncogene. 2017 Jun 29;36(26):3651-3660. doi: 10.1038/onc.2016.515. Epub 2017 Feb 13.

40.

'Trained immunity': consequences for lymphoid malignancies.

Stevens WB, Netea MG, Kater AP, van der Velden WJ.

Haematologica. 2016 Dec;101(12):1460-1468. Epub 2016 Nov 10. Review.

41.

Innate lymphoid cells are expanded and functionally altered in chronic lymphocytic leukemia.

de Weerdt I, van Hoeven V, Munneke JM, Endstra S, Hofland T, Hazenberg MD, Kater AP.

Haematologica. 2016 Nov;101(11):e461-e464. Epub 2016 Aug 4. No abstract available.

42.

Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection.

van der Valk M, Zaaijer HL, Kater AP, Schinkel J.

J Hepatol. 2017 Jan;66(1):242-243. doi: 10.1016/j.jhep.2016.09.014. Epub 2016 Oct 1. No abstract available.

PMID:
27702641
43.

TP53 dysfunction in CLL: Implications for prognosis and treatment.

Te Raa GD, Kater AP.

Best Pract Res Clin Haematol. 2016 Mar;29(1):90-99. doi: 10.1016/j.beha.2016.08.002. Epub 2016 Aug 11. Review.

PMID:
27742075
44.

The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Thijssen R, Ter Burg J, van Bochove GG, de Rooij MF, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MH, Eldering E, Kersten MJ, Kater AP.

Leukemia. 2016 Sep;30(9):1963. doi: 10.1038/leu.2016.184. No abstract available.

PMID:
27600169
45.

Macrophage-mediated chronic lymphocytic leukemia cell survival is independent of APRIL signaling.

van Attekum M, Terpstra S, Reinen E, Kater AP, Eldering E.

Cell Death Discov. 2016 Mar 21;2:16020. doi: 10.1038/cddiscovery.2016.20. eCollection 2016.

46.

Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia.

Siska PJ, van der Windt GJ, Kishton RJ, Cohen S, Eisner W, MacIver NJ, Kater AP, Weinberg JB, Rathmell JC.

J Immunol. 2016 Sep 15;197(6):2532-40. doi: 10.4049/jimmunol.1502464. Epub 2016 Aug 10.

47.

Chronic lymphocytic leukemia development is accelerated in mice with deficiency of the pro-apoptotic regulator NOXA.

Slinger E, Wensveen FM, Guikema JE, Kater AP, Eldering E.

Haematologica. 2016 Sep;101(9):e374-7. doi: 10.3324/haematol.2016.142323. Epub 2016 Jun 13. No abstract available.

48.

The APRIL paradox in normal versus malignant B cell biology.

van Attekum MH, Kater AP, Eldering E.

Cell Death Dis. 2016 Jun 23;7(6):e2276. doi: 10.1038/cddis.2016.183. No abstract available.

49.

Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.

Thijssen R, Ter Burg J, Garrick B, van Bochove GG, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IA, van Kampen RJ, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP.

Blood. 2016 Jul 28;128(4):574-83. doi: 10.1182/blood-2016-02-700328. Epub 2016 May 27.

PMID:
27235137
50.

T-cells fighting B-cell lymphoproliferative malignancies: the emerging field of CD19 CAR T-cell therapy.

Heijink DM, Kater AP, Hazenberg MD, Hagenbeek A, Kersten MJ.

Neth J Med. 2016 May;74(4):147-51. Review.

Supplemental Content

Loading ...
Support Center